Innovative strategies in metastatic gastric cancer: a  short review
SummaryRecent innovative advances, especially concerning immunotherapeutic agents and targeted therapies, have changed the face of modern oncology. The year 2020 represents a  milestone in the treatment of gastroesophageal cancer because several trials showed promising survival benefits, at least for a specific subgroup of patients. Not only immunotherapeutic agents, but also targeted therapies seem to be beneficial, particularly when the target is well defined and the threshold value is selected appropriately. Thus, many new innovative treatment strategies are underway and might lead to a further paradigm c...
Source: Memo - Magazine of European Medical Oncology - October 19, 2021 Category: Cancer & Oncology Source Type: research

Practical considerations for the management of  immune thrombocytopenic purpura
SummaryImmune thrombocytopenic purpura (ITP) is a  rare hematological disorder with an autoimmune-mediated, often dramatic reduction of platelets in peripheral blood. Thrombocytopenia results from a reduced life span of thrombocytes and an additionally decreased production in bone marrow. For decades, the first-line therapy for ITP has been corti costeroids. As significant thrombocytopenic bleedings occur, the use of additional medication may be needed. Recent updates on therapy guidelines recommend the shortest possible use of corticosteroids. Thrombopoietin-receptor agonists are often used second line. Today sp...
Source: Memo - Magazine of European Medical Oncology - October 18, 2021 Category: Cancer & Oncology Source Type: research

ASCO  2021—selection of personal highlights in early stage non-small cell lung cancer
In conclusion ASCO 2021 provided the lung cancer community with inspiring new data especial in early stages and challenges the community with integration of these data into our daily clinical routine. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 18, 2021 Category: Cancer & Oncology Source Type: research

Report from the Virtual American Society of Clinical Oncology (ASCO) Annual Meeting, 4th -8th June 2021, the 26th European Hematology Association (EHA) 2021 Virtual Congress, 9th -17th June 2021, and the Virtual 17th International Conference on Malignant Lymphoma (ICML), 18th -22nd June 2021
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 13, 2021 Category: Cancer & Oncology Source Type: research

Pancytopenia —a diagnostic challenge?
SummaryPancytopenia is a  condition in which there is a lower-than-normal number of red and white blood cells and platelets in the blood. The spectrum of causes for the decrease of one or more blood cell lineages is broad including increased destruction, pooling by spleen, loss of blood cells, decreased production due to toxic and/or immune-mediated mechanisms and abnormalities due to clonal/malignant hematopoiesis. In this article common and/or typical causes of pancytopenia are presented with special emphasis on more or less disease specific features that may be useful clues in the differential diagnosis of thi...
Source: Memo - Magazine of European Medical Oncology - October 12, 2021 Category: Cancer & Oncology Source Type: research

ASCO 2021: Highlights in central nervous system tumors
SummaryMore than 140 abstracts were presented in the Central Nervous System Tumors track during the 2021 American Society of Clinical Oncology (ASCO) virtual meeting. Here, we review our personal highlights of the presented data. In rare entities such as papillary craniopharyngioma and neurotrophic tyrocine receptor kinase (NTRK)-fusion-positive tumors, promising data on targeted therapies were reported. In addition, early data on olaparib in high-grade glioma and combinational immunotherapy approaches will be briefly reviewed. Furthermore, the eagerly awaited results of the EORTC-1709 phase  III trial on the pan-prot...
Source: Memo - Magazine of European Medical Oncology - October 11, 2021 Category: Cancer & Oncology Source Type: research

ASCO 2021 –Gastroesophageal tumor highlights
SummaryThe oncological community witnessed several practice-changing clinical reports in this years ’ annual congress of the American Society of Clinical Oncology (ASCO). Many immunotherapeutic agents were shown to be beneficial for upper gastrointestinal tumors. For advanced squamous cell carcinoma, immunotherapy and chemotherapy combinations revealed by the CheckMate 648 and ESCORT-1st trials have been implemented into the clinical practice. The updates on the CheckMate 649 and CheckMate 577 trials again underlined the significant clinical contribution of nivolumab in advanced and localized gastroeso...
Source: Memo - Magazine of European Medical Oncology - October 8, 2021 Category: Cancer & Oncology Source Type: research

Checkpoint inhibitor pneumonitis: Short review of literature and case report
SummaryImmune checkpoint blockade (ICB) has fundamentally improved the treatment landscape of advanced lung cancer. Improved tolerability and encouraging duration of response in selected patients are some of the advantages of ICB over conventional cytotoxic chemotherapies. However, immune-related adverse events (irAEs) possibly affecting multiple organs pose challenges in diagnosis and management. Checkpoint inhibitor pneumonitis (CIP) is a rare but clinically highly relevant irAE that can significantly impair quality of life and can be potentially life threatening. Since its heterogeneity in clinical and radiographic pres...
Source: Memo - Magazine of European Medical Oncology - October 6, 2021 Category: Cancer & Oncology Source Type: research

New actionable targets and investigational drugs in chronic lymphocytic leukemia
SummaryThe treatment landscape of chronic lymphocytic leukemia (CLL) has shifted from chemotherapy-based approaches to targeted agents in the last decade. However, evolving drug resistance and accumulating toxicity remain challenges that still limit patients ’ clinical outcomes. Furthermore, currently licensed targeted agents such as inhibitors of Bruton’s tyrosine kinase (BTK) and anti-apoptotic protein B‑cell lymphoma 2 (BCL2) do not adequately compensate for the poor clinical outcomes associated with high-risk genetics such as TP53 alterations . New insights into disease biology facilitated design and...
Source: Memo - Magazine of European Medical Oncology - October 5, 2021 Category: Cancer & Oncology Source Type: research

Is thymus and activation-regulated chemokine a  forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?
ConclusionReviewed studies suggest that TARC is one of the most promising markers, which can be used to improve treatment outcome in cHL. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 4, 2021 Category: Cancer & Oncology Source Type: research

Best of ASCO 2021: new data from triple-negative breast cancer
SummaryThis year ’s ASCO Annual Meeting has been a showcase for the overwhelming success of novel, targeted therapies, particularly in a tumor entity that has – until recently – been felt to be only treatable with chemotherapy. New data are extremely encouraging, but also highlight the need for target identi fication beyond the classical clinicopathological factors. Both, the Olympia and the Neotala study have been performed in BRCA-mutated tumors, and their results clearly point to the necessity to offer germline testing to HER2-negative high risk early breast cancer. In addition, GeparNuevo on...
Source: Memo - Magazine of European Medical Oncology - October 4, 2021 Category: Cancer & Oncology Source Type: research

Is thymus and activation-regulated chemokine a  forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?
ConclusionReviewed studies suggest that TARC is one of the most promising markers, which can be used to improve treatment outcome in cHL. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 4, 2021 Category: Cancer & Oncology Source Type: research

Best of ASCO 2021: new data from triple-negative breast cancer
SummaryThis year ’s ASCO Annual Meeting has been a showcase for the overwhelming success of novel, targeted therapies, particularly in a tumor entity that has – until recently – been felt to be only treatable with chemotherapy. New data are extremely encouraging, but also highlight the need for target identi fication beyond the classical clinicopathological factors. Both, the Olympia and the Neotala study have been performed in BRCA-mutated tumors, and their results clearly point to the necessity to offer germline testing to HER2-negative high risk early breast cancer. In addition, GeparNuevo on...
Source: Memo - Magazine of European Medical Oncology - October 4, 2021 Category: Cancer & Oncology Source Type: research

Ponatinib and palbociclib combination in TKI-resistant CML —A case report
ConclusionThis combination treatment showed high clinical activity. However, biological activity needs to be further characterized in prospective clinical trials. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 20, 2021 Category: Cancer & Oncology Source Type: research

A GLOBAL CONGRESS DIGEST ON SOLID TUMORS. Report from the ASCO Virtual Congress, 4th –8th June 2021
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 9, 2021 Category: Cancer & Oncology Source Type: research

Immune-related hepatitis in a  patient with hepatocellular carcinoma treated with nivolumab
We present a  case of a male patient with advanced hepatocellular carcinoma who developed hepatic and dermatological immune-related adverse events during treatment with the immune checkpoint inhibitor nivolumab. We discuss relevant aspects regarding the management of immune-related hepatic adverse events, incl uding the incidence and onset of the event, the requirement for immune-modulating medication, resuming of immunotherapy, and the association between the occurrence of immune-related adverse events and the outcome. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 9, 2021 Category: Cancer & Oncology Source Type: research

Report on Lung Cancer from the ASCO 2021 virtual congress, June 4th –8th
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 8, 2021 Category: Cancer & Oncology Source Type: research

Neoadjuvant versus adjuvant management of resectable pancreas cancer: A  review of the literature
SummaryNeoadjuvant therapy is well-accepted in the treatment of borderline resectable and locally advanced PC, the benefit of neoadjuvant chemotherapy in patients with resectable disease, however,   is currently not so clear. Here we provide an up date on the literature. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 8, 2021 Category: Cancer & Oncology Source Type: research

Report on Lung Cancer from the ASCO 2021 virtual congress, June 4th –8th
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 8, 2021 Category: Cancer & Oncology Source Type: research

Neoadjuvant versus adjuvant management of resectable pancreas cancer: A  review of the literature
SummaryNeoadjuvant therapy is well-accepted in the treatment of borderline resectable and locally advanced PC, the benefit of neoadjuvant chemotherapy in patients with resectable disease, however,   is currently not so clear. Here we provide an up date on the literature. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 8, 2021 Category: Cancer & Oncology Source Type: research

Therapy concepts in the context of precision medicine for pediatric malignancies —children are not adults
SummaryCancer remains the leading cause of death from disease among children beyond the age of one. Survival of pediatric patients with cancer has dramatically improved over the last decades but some tumors remain almost intractable and relapse is still associated with an infaust prognosis. Despite the heterogeneity of pediatric malignancies, most treatments include the same set of generic therapies.  Optimizing delivery of conventional therapeutics has been the driving force behind continuous improvements but further escalation of conventional therapy is unlikely to improve outcomes. The limited success of targeted d...
Source: Memo - Magazine of European Medical Oncology - September 3, 2021 Category: Cancer & Oncology Source Type: research

Pediatric oncology 2.0 —shaping the future with precision
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

Best of SABCS 2020
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

Sphenoidal mucormycosis associated with large B-cell lymphoma: case report and literature review
We report a case of sphenoid al mucormycosis in a patient with large B‑cell lymphoma. This complication happened before any chemotherapy. The patient had normal neutrophils count and his diabetes was well controlled. Clinical course and management are discussed along with a review of the literature. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

Interesting news from the annual meeting of the American Society of Hematology 2020
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

Clinically relevant infections in hematatology and oncology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

Pediatric oncology 2.0 —shaping the future with precision
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

Best of SABCS 2020
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

Interesting news from the annual meeting of the American Society of Hematology 2020
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

Clinically relevant infections in hematatology and oncology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

San Antonio 2020 update —the top 3 surgical abstracts
SummaryThe San Antonio Breast Cancer Symposium is one of the largest meetings addressing the treatment of breast cancer patients; therefore, the meeting is of high interest for breast cancer specialists from around the world.From the meeting in 2020, which was held virtually, I have picked the top three surgical abstracts to show new developments in the surgical treatment of breast cancer patients.The first abstract addresses the question of whether an axillary dissection is necessary or not, in a selected patient cohort. The results, even after a short follow-up time, could confirm the findings of the ACOZOG Z 0011 trial....
Source: Memo - Magazine of European Medical Oncology - September 1, 2021 Category: Cancer & Oncology Source Type: research

The double-edged sword of immune checkpoint inhibition in advanced staged thymic epithelial tumours
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 20, 2021 Category: Cancer & Oncology Source Type: research

Rare lung cancers —Primary pulmonary leiomyosarcoma: A case report
SummaryPrimary pulmonary sarcomas (PPS) are rare mesenchymal lung cancers, which do not present clinically or radiological different to lung carcinomas. Definite PPS diagnosis can only be made by histological analysis and detailed staging examinations in order to exclude a  secondary pulmonary malignancy such as metastatic soft tissue sarcoma or another solid tumour. Here we present the case of a 66-year-old woman with a pulmonary mass infiltrating the diaphragm and the mediastinal adipose tissue, which was identified as leiomyosarcoma. The patient received curativ e surgery with complete tumour R0 resection...
Source: Memo - Magazine of European Medical Oncology - August 20, 2021 Category: Cancer & Oncology Source Type: research

The double-edged sword of immune checkpoint inhibition in advanced staged thymic epithelial tumours
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 20, 2021 Category: Cancer & Oncology Source Type: research

Rare lung cancers —Primary pulmonary leiomyosarcoma: A case report
SummaryPrimary pulmonary sarcomas (PPS) are rare mesenchymal lung cancers, which do not present clinically or radiological different to lung carcinomas. Definite PPS diagnosis can only be made by histological analysis and detailed staging examinations in order to exclude a  secondary pulmonary malignancy such as metastatic soft tissue sarcoma or another solid tumour. Here we present the case of a 66-year-old woman with a pulmonary mass infiltrating the diaphragm and the mediastinal adipose tissue, which was identified as leiomyosarcoma. The patient received curativ e surgery with complete tumour R0 resection...
Source: Memo - Magazine of European Medical Oncology - August 20, 2021 Category: Cancer & Oncology Source Type: research

Innovative therapy concepts for pediatric brain tumors
SummaryIn recent years, novel insight into molecular mechanisms has allowed the identification of drug targets for various pediatric brain tumors. The aim of this article is to give an overview of new treatment options in neurofibromatosis type  1 (NF1), novel tyrosine kinase inhibitors that target oncogenic gene fusions in pediatric brain tumors, and antiangiogenesis as promising therapy especially in recurrent medulloblastoma. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 19, 2021 Category: Cancer & Oncology Source Type: research